G protein pathway suppressor 2 suppresses gastric cancer by destabilizing epidermal growth factor receptor

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• G protein pathway suppressor 2 (GPS2) is widely expressed but its role in cancer, particularly gastric cancer (GC), is unclear.
• Understanding GPS2's function is crucial for identifying new therapeutic targets in GC.

Purpose of the Study:

• To investigate the role and molecular mechanisms of GPS2 in gastric cancer progression.
• To explore the potential of the GPS2-EGFR axis as a therapeutic target in GC.

Main Methods:

• Analysis of GPS2 expression in GC tissues and correlation with clinicopathological features and survival.
• Experimental manipulation of GPS2 expression in GC cells to assess effects on proliferation, invasion, and tumorigenesis.
• Investigation of GPS2's effect on epidermal growth factor receptor (EGFR) signaling and degradation pathways, including ubiquitination and lysosomal degradation.
• Assessment of GPS2's impact on autophagy.

Main Results:

• GPS2 expression is significantly downregulated in GC tissues and associated with advanced pathological grade, lymph node metastasis, and deeper invasion.
• Low GPS2 expression predicts poorer overall survival in GC patients.
• Overexpression of GPS2 inhibits GC cell proliferation, colony formation, tumorigenesis, and invasion.
• GPS2 reduces EGFR protein levels and downstream signaling by promoting EGFR ubiquitination and lysosomal degradation, enhanced by c-Cbl.
• GPS2 activates autophagy and promotes autophagic flux through EGFR destabilization.

Conclusions:

• Downregulation of GPS2 is linked to gastric cancer progression and poor patient outcomes.
• GPS2 functions as a tumor suppressor in GC by targeting EGFR for lysosomal degradation and activating autophagy.
• The GPS2-EGFR axis represents a promising therapeutic target for gastric cancer treatment.